Login
Navigate Fool.com
Will AMRN beat
the market?

Amarin Corp plc (ADR) (NASDAQ: AMRN)

Community Rating: 3 Stars: Appealing

1.50 -0.07 (-4.46%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.55
Previous Close $1.57
Daily Range $1.49 - $1.58
52-Week Range $1.28 - $7.40
Market Cap $259.4M
P/E Ratio -1.57
Dividend (Yield) $0.00 (0.0%)
Volume 2,360,188
Average Daily Volume 1,690,632
Current FY EPS -$0.57

How do you think AMRN
will perform against the market?

Top AMRN Bull/Bear Pitches

 

genedom (< 20)
Submitted August 15, 2012

Excellent fundamental and technical setting. Will see 18-20 by year end.

0 Replies Reply Report this Post
 

chris293 (< 20)
Submitted May 7, 2013

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

1 Replies Reply Report this Post

News & Commentary Rss Feed

3 Things to Look for in MannKind's Partnership

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

Shire Retreats for Second Day Since Abbvie's Revised Bid as European ADRs Decline; Portugal Telecom

Shire Retreats for Second Day Since Abbvie's Revised Bid as European ADRs Decline; Portugal Telecom Gains

European ADRs Post Broad Declines After European Markets Weaken on German, U.K. Economic Data

Of These 3 Battleground Biotech Stocks, 1 Is a Buy

Do Amarin, Prosensa, and Jazz Pharmaceuticals deserve a goal, a yellow card, or a straight stay-away red card?

Biotech 101: Off-Label Prescriptions

Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.

Amarin Leads Gains in European ADRs After Favorable Journal Article; Nokia Down on Amazon.com Phone

European ADRs Show Broad Declines After Region's Markets Pressured by

AstraZeneca's Fishy FDA Approval

AstraZeneca's Epanova joins the list of omega-3 fish oil drugs that includes GlaxoSmithKline's Lovaza and Amarin's Vascepa.

Why Amarin Corporation PLC Shares Tumbled

A "switch-a-roo" at Amarin's subsidiary gives existing shareholders indigestion. However, that's not even the company's biggest problem.

Top Analyst Upgrades and Downgrades: Amarin, Boeing, Cisco, KKR, NetApp, Twitter and More

See More AMRN News...

Sector

Healthcare

Industry

Drugs

Amarin Corp plc (ADR) (AMRN) Description

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders. Website: http://www.amarincorp.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks